Perioperative Management of Anticoagulation: Can You Clear My Patient for a Procedure?

Thursday | January 27, 2022 | 12:00 - 1:00pm ET
9:00 PT | 10:00 MT | 11:00 CT

Periprocedural management of antithrombotics is a common but challenging clinical scenario that renders patients vulnerable to potential adverse events such as bleeding and thrombosis. Over the past decade, periprocedural antithrombotic approaches have changed considerably with the advent of direct oral anticoagulants (DOACs), as well as a paradigm shift away from bridging in many warfarin patients.

Join five AC Forum Board members for a webinar that reviews this recent publication and discusses practical, stepwise approaches to periprocedural management of antithrombotic agents using case-based examples of relevant clinical scenarios.

Presenters:
- Andrea Van Beek, RN, DNP, AGPCNP-BC
- Allison Burnett, PharmD, PhC, CACP
- Scott Kaatz, DO, MSc, FACP, SFHM
- Bishoy Ragheb, PharmD, BCACP, CACP

Moderator:
- Arthur Allen, PharmD, CACP

We are pleased to provide enduring accreditation for this webinar!

REGISTER NOW
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Anticoagulation Forum. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
Amedco LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.

Pharmacists
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

Now Available - December Webinar Recording

Could I Have Prevented a Stroke?

Health Disparities are systematic differences in the health status of population groups that are closely linked to social, economic, and environmental disadvantages. Implicit bias, language barriers, and a lack of cultural sensitivity all contribute to the quality of care a patient receives.

In this webinar, we discuss how an understanding of the social determinants of health can inform how practitioners engage with patients, and introduce a new AC Forum Rapid Resource on this important topic.

We are pleased to provide 1 hour of Enduring Ethics credit for this webinar!

Interested in viewing our enduring webinars? Visit our website

PAD Learning Series
Join faculty experts from the Anticoagulation Forum, American College of Cardiology, American Society of Health System Pharmacists, and the Society for Vascular Medicine in a multi-video learning series as they evaluate current evidence, suggest practical improvements to clinical management of PAD, and highlight a new rapid resource.
This program is accredited for up to 2.25 hours of continuing education credits for physicians, nurses, and pharmacists.

**Rapid Resource: Antithrombotic Management Following PAD Revascularization**

This 1-page clinical guidance from the Anticoagulation Forum summarizes management strategies for PAD after revascularization including initiation of therapy, 30-day follow up, and risk factors in the context of current guidance.

**Faculty:**
- Geoffrey Barnes, MD, MSc
- Sahil Parikh, MD
- Diane Wirth, ANP, CACP

This project was supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

The content was developed independently by the Anticoagulation Forum. The funder had no input in the content of the Rapid Resource or presentations.

**CVS Caremark/Zink Formulary Changes for DOACs**
CVS Caremark/Zinc has changed several formularies for commercial health plans, restricting anticoagulants to only rivaroxaban and warfarin. Clinicians are advised to proactively identify affected patients under their care and take steps to assure uninterrupted access to appropriate anticoagulation therapy.

More Information & AC Forum Recommendations

New Oral COVID-19 Treatment and Anticoagulant Interactions

On December 22, 2021 the FDA released an Emergency Use Authorization for Pfizer’s Paxlovid™ (nirmatrelvir tablets; ritonavir tablets), an oral treatment for mild to moderate COVID-19 in patients who are at high risk for progression to severe COVID-19, including hospitalization or death.

Paxlovid™ is administered as three pills (two of nirmatrelvir and one of ritonavir) twice daily for 5 days, for a total of 30 pills. It must be given within 5 days of symptom onset and is not authorized for use longer than 5 days.

Since Paxlovid™ contains ritonavir, there exists the potential for clinically relevant drug-drug interactions (DDIs) with all oral anticoagulants (DOACS and warfarin) during the 5-day course of therapy, due to ritonavir being a combined P-gp inhibitor and strong CYP3A4 inhibitor.

Clinicians are advised to consider the potential impact of DDIs as they manage anticoagulated patients with acute COVID-19 infections. If the anticoagulation provider is able to identify and intervene in a timely manner, the following is recommended:

- Close monitoring of warfarin and possible warfarin dose adjustment
- Management of the DOACs can depend on indication, renal function, and other factors.
  - For patients taking apixaban 10mg or 5mg twice daily, consider reducing the dose to 5mg or 2.5mg twice daily, respectively, for the 5-day duration of the Paxlovid™
  - For patients taking rivaroxaban, edoxaban, or apixaban 2.5mg, consider individualized risk of thromboembolism/bleeding
- Counsel patient to monitor and report bleeding symptoms

For additional details and specific recommendations consider the following AC Forum Resources:

Rapid Resource on DDIs with DOACs

DOAC Playbook

Rapid Resources and Literature Updates!

Curated Online Literature Tool
Our online curated literature tool is updated twice a month and provides you with the opportunity to stay up to date on the most recent articles and publications.

Search by date, topic, or key words, or use our Rapid Recap to view the most impactful articles.

**Latest Highlights:**
- Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus
- Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
- Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial
- Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis
- Informing the Choice of Direct Oral Anticoagulant Therapy in Patients With Atrial Fibrillation

**Top Anticoagulation Papers July-Dec 2021**

Over 1,000 anticoagulation-related papers have been posted to our Literature Update website since last summer, but only a small number were selected each 2-week cycle to have “stars upon thars”. Ring in the new year by reviewing this list of manuscripts by viewing the summary document or by visiting the Literature Update Website and sort by Star column.

**Rapid Recap Newsletter**

The Recap Newsletter aims to distill the top three to eight articles from the last 30 days into a one-page bite sized summary. This newsletter will be published once a month.

View the latest December 2021 Rapid Recap [here](#).

Access all Rapid Recap Newsletters

Special thanks to Dr. Candace Bryant, PharmD for editing and coordinating this initiative, as well as other editorial teams that will be assisting with publishing upcoming editions.
New Rapid Resources

Antithrombotic Management Following PAD Revascularization, Nov. 2021

Left Atrial Appendage Occlusion (LAAO) Devices for Prevention of Stroke and Systemic Embolism in Atrial Fibrillation, Dec. 2021

Social Determinants of Health & Patient Care, Dec. 2021

Venous Thromboembolism (VTE) Prophylaxis in Acutely Ill Medical Patients, Dec. 2021

View all Rapid Resources

AC Forum IDEA Initiative

Inclusion, Diversity, Equity, and Allyship

The AC Forum IDEA Initiative works to increase awareness and promote diversity in our leadership, membership, and programming.

Health Disparities & Patient Care
Kimberly Terry, PharmD, BCPS, BCCCP

This review of internal and systemic strategies for promoting health equity helps providers to define health disparities and the role social and economic factors play in overall health and well-being.

Listen to Recording!

Highlight Video:
Could I have Prevented a Stroke?

This short 2 minute video highlights how health disparities impact a patient's access to quality health care and anticoagulation therapy.

Watch the Video

Recommended Reading

How to Meaningfully Address Race and Identity With Your Patients
Andrea Garavito Martinez and Erika Sullivan

Is it Time to Say R.I.P. to 'POC'?
S.M. Meraji, N. Escobar and K. Devarajan

From Our Sponsors
Practical Management of Anticoagulation for Impella Percutaneous Mechanical Circulatory Support

Available February 2022

The presentation will include a Panel discussion on the AC Forum’s recently developed Rapid Resource: **Practical Management of Anticoagulation for Impella Percutaneous Mechanical Circulatory Support**

**Panelists:**
- Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP
- Allison Burnett, PharmD, PhC, CACP
- Douglas Jennings, PharmD, FACC, FAHA, FHSFA, FCCP, BCPS

Developed by Craig Beavers, Allison Burnett, & Douglas Jennings

To submit questions in advance or to be added to the distribution list please email mdyan@abiomed.com

---

**Cardiac Monitoring for Data-guided Atrial Fibrillation Management**

Tuesday | February 15, 2022 | 3:00pm ET
12:00pm PT | 1:00pm MT | 2:00pm CT

Join Medtronic for an educational program on cardiac monitoring strategies for data-guided decisions in the management of atrial fibrillation including anticoagulation and antiarrhythmic decisions.

**Featuring:**

**William E. Dager**, Pharm.D., BCPS, MCCM, FASHP, FACC, FCSHP
Pharmacist | UC Davis Medical Center | Sacramento, CA
AC Forum Board Member

**David S. Frankel, M.D.**
Associate Professor of Medicine,
Electrophysiology Section | Cardiovascular Division
Hospital of the University of Pennsylvania | Philadelphia, PA

For more information and to register, [Click Here](#).
Researchers at the Beth Israel Deaconess Medical Center in Boston have partnered with The National Blood Clot Alliance, through a cooperative agreement with the Centers for Disease Control and Prevention (CDC) to explore the use of venous thromboembolism risk reduction strategies for hospitalized medical patients. As part of this initiative, they are conducting a survey to better understand how clinicians, like yourself, utilize mechanical and pharmacologic prophylaxis for hospitalized adult patients.

Please participate and take this important survey today.

---

The combination of patient surges and staffing shortages has created an unprecedented strain on the healthcare system. In light of this, the THSNA Board of Directors has decided to postpone THSNA 2022 until August 25th-27th with the pre-conference workshops now occurring on August 24th.

THSNA meeting registrants will have the option of remote attendance via live streams of all talk sessions, followed by on-demand access to recordings of all sessions for both live and virtual attendees.

*NEW* Abstract Submission Deadline: April 29, 2022
For more information on abstract submission, please visit: here

Regular Registration Deadline: July 1, 2022
Click Here to Register

Join Your Colleagues at THSNA 2022. As a reminder, when registering select that you are a member of AC Forum!
Thank You to Our Newsletter Sponsors

- Janssen
- Bristol Myers Squibb
- Pfizer
- ABIOMED
- Acelis Connected Health
- Alexion
- Boston Scientific
- Medtronic
- werfen